Investigational Drug Details
| Drug ID: | D037 |
| Drug Name: | Bifidobacterium longum |
| Synonyms: | Bifidobacterium infantis; Bifidobacterium infantis whole; Bifidobacterium lactentis whole; Bifidobacterium liberorum whole; Bifidobacterium longum bv. infantis whole; Bifidobacterium longum infantis whole; Bifidobacterium longum subsp. infantis; Bifidobacterium longum subsp. infantis whole |
| Type: | Biological drug |
| DrugBank ID: | DB14222 |
| DrugBank Description: | -- |
| PubChem ID: | 9047 |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (IRCT201301223140N6) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0635 | IRCT201301223140N6 | Phase 2 | Not Recruiting | No Results Available | 16/01/2014 | 22 February 2018 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A06909 | 32700545 | Biol Res Nurs | Oral Probiotic Bifidobacterium Longum Supplementation Improves Metabolic Parameters and Alters the Expression of the Renin-Angiotensin System in Obese Mice Liver. | Details |
| A08101 | 32245586 | Chin J Nat Med | Selenium-enriched Bifidobacterium longum protected alcohol and high fat diet induced hepatic injury in mice. | Details |
| A09484 | 31726978 | BMC Genomics | Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. | Details |
| A12812 | 30272851 | Asia Pac J Clin Nutr | Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease. | Details |
| A13702 | 29800811 | J Nutr Biochem | Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models. | Details |
| A14502 | 29379536 | Arch Med Sci | Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? | Details |
| A15796 | 28705785 | Turk J Gastroenterol | Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis. | Details |
| A18939 | 26858714 | Front Microbiol | Ethanol Production by Selected Intestinal Microorganisms and Lactic Acid Bacteria Growing under Different Nutritional Conditions. | Details |
| A25013 | 22247604 | J Clin Biochem Nutr | Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. | Details |
| A25385 | 21901256 | Dig Dis Sci | Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. | Details |
| A31765 | 29900399 | Data Brief | The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment. | Details |